Targacept to Present at the Stifel Nicolaus 2012 Healthcare Conference

  Targacept to Present at the Stifel Nicolaus 2012 Healthcare Conference

Stifel Nicolaus Healthcare Conference 2012

Business Wire

WINSTON-SALEM, N.C. -- August 29, 2012

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics (TM), today announced that Alan A. Musso,
Senior Vice President, Finance and Administration and Chief Financial Officer,
is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference at
Four Seasons Hotel Boston on Wednesday, September 5, 2012 at 1:30 p.m. Eastern

The presentation will be webcast and accessible from the Investor Relations
page of Targacept’s website, www.targacept.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15 minutes
prior to the scheduled start time. An archived version of the webcast will be
available for replay on the Investor Calendar section of the Investor
Relations page of Targacept’s website for at least two weeks following the

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics^TM
for difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
Phase 2 product candidates representing first-in-class opportunities.
Targacept leverages its scientific leadership and proprietary drug discovery
platform Pentad^TM to fuel its pipeline and attract significant collaborations
with global pharmaceutical companies. For more information, please visit

Building Health, Restoring Independence^®


Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.